Telix Pharmaceuticals Limited (TLPPF)

Telix Pharmaceuticals Income Statement

Financials in millions AUD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Revenue	502.55	155.98	4.9	4.68	3.49
Revenue Growth (YoY)	222.18%	3084.65%	4.66%	34.29%	1685.88%
Cost of Revenue	187.76	61.56	2.55	2.02	2.54
Gross Profit	314.79	94.43	2.35	2.66	0.94
Selling, General & Admin	134.43	93.5	40.81	19.21	11.59
Research & Development	128.84	57.86	34.14	23.09	21.16
Other Operating Expenses	-29.34	3.09	23.55	2.96	11.44
Operating Expenses	263.27	189.44	101.15	52.44	41.2
Operating Income	51.51	-92.21	-75.25	-46.76	-28.71
Interest Income	1.02	0	0	0.07	0.1
Interest Expense	0.99	6.42	5.22	1.18	2.41
Other Expense / Income	48.45	0	-	0.07	0.1
Pretax Income	3.09	-98.62	-80.47	-47.94	-31.12
Income Tax	-2.12	5.46	0.05	-3.05	-3.26
Net Income	5.21	-104.08	-80.51	-44.89	-27.87
Shares Outstanding (Basic)	319	311	282	257	233
Shares Outstanding (Diluted)	324	311	282	257	233
Shares Change	4.21%	10.08%	9.69%	10.21%	15.49%
EPS (Basic)	0.02	-0.34	-0.29	-0.17	-0.12
EPS (Diluted)	0.02	-0.34	-0.29	-0.17	-0.12
Free Cash Flow	13.09	-77.83	-60.67	1.64	-23.8
Free Cash Flow Per Share	0.04	-0.25	-0.21	0.01	-0.10
Gross Margin	62.64%	60.54%	47.98%	56.75%	27.03%
Operating Margin	10.25%	-59.11%	-1536.28%	-999.15%	-823.93%
Profit Margin	1.04%	-66.72%	-1643.73%	-959.12%	-799.63%
Free Cash Flow Margin	2.60%	-49.90%	-1238.61%	35.00%	-682.96%
Effective Tax Rate	-68.80%	-	-	-	-
EBITDA	58.44	-86.83	-70.07	-41.88	-24.48
EBITDA Margin	11.63%	-55.66%	-1430.65%	-894.83%	-702.38%
Depreciation & Amortization	6.92	5.38	5.17	4.88	4.24
EBIT	51.51	-92.21	-75.25	-46.76	-28.71
EBIT Margin	10.25%	-59.11%	-1536.28%	-999.15%	-823.93%

Sources: The data provider is Financial Modeling Prep and the numbers are sourced from SEC filings.